M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

Phase 3

Conditions: Prostate Cancer

Interventions: Radiation: Hypofractionated Intensity Modulated Radiotherapy
Radiation: Conventional Fractionated Intensity Modulated Radiotherapy

First Posted Date: 2008-04-28

Last Posted Date: 2021-01-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 225

Registration Number: NCT00667888

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: 2CdA
Drug: Cyclophosphamide
Drug: Rituximab

First Posted Date: 2008-04-28

Last Posted Date: 2022-03-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00667329

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Genetic Differences in Limbic Activation Associated With Nicotine Withdrawal

Phase 3

Completed

Conditions: Smoking

Interventions: Other: Functional Magnetic Resonance Imaging (fMRI)

First Posted Date: 2008-04-23

Last Posted Date: 2012-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 64

Registration Number: NCT00664404

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Sexual Behavior in Head and Neck Cancer Patients

Conditions: Oropharyngeal Cancer
Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2008-04-21

Last Posted Date: 2020-12-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1500

Registration Number: NCT00662662

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients

Phase 1

Completed

Conditions: Multiple Myeloma
Stem Cell Transplantation

Interventions: Drug: Arsenic Trioxide
Drug: Melphalan
Drug: Ascorbic Acid

First Posted Date: 2008-04-18

Last Posted Date: 2013-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00661544

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Efficacy of the Third Eye Retroscope Auxiliary Imaging System

Not Applicable

Completed

Conditions: Colorectal Cancer

Interventions: Device: Third Eye Retroscope Auxiliary Imaging System

First Posted Date: 2008-04-14

Last Posted Date: 2013-12-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 288

Registration Number: NCT00657371

Locations: 🇺🇸
El Camino Hospital, Mountain View, California, United States
🇺🇸
Washington University, St. Louis, Missouri, United States
🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States

and more 4 locations

Setup Variation in the Supraclavicular Lymph Nodes Treatment in Breast Cancer Patients

Completed

Conditions: Breast Cancer

Interventions: Procedure: CBCT Scan
Procedure: OBI KV Imaging

First Posted Date: 2008-04-14

Last Posted Date: 2015-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00658281

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

Phase 2

Terminated

Conditions: Bronchiolitis

Interventions: Drug: Fluticasone Propionate

First Posted Date: 2008-04-11

Last Posted Date: 2012-04-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00656916

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)

Interventions: Drug: Idarubicin
Drug: Cytarabine
Drug: Vorinostat

First Posted Date: 2008-04-11

Last Posted Date: 2015-03-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 106

Registration Number: NCT00656617

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS

Phase 3

Completed

Conditions: Acute Myelogenous Leukemia
Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Procrit

First Posted Date: 2008-04-11

Last Posted Date: 2018-05-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 51

Registration Number: NCT00656448

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy